围手术期化疗在原发高级别肢体软组织肉瘤中的作用:基于PERSARC的风险分层分析
该回顾性队列研究纳入5683例18-70岁原发高级别肢体软组织肉瘤患者,评估围手术期化疗对总生存的影响,并分析PERSARC工具能否识别获益人群。加权Kaplan-Meier曲线显示总体人群无获益,但高PERSARC风险组中蒽环类+异环磷酰胺方案5年OS显著优于未化疗(69.8% vs 59.0%,p=0.004,HR 0.66,95%CI 0.53-0.83)。
要点
- 总体人群中围手术期化疗未显示对总生存有益。
- 高PERSARC风险组中蒽环类+异环磷酰胺方案5年OS为69.8%,未化疗为59.0%。
- 高PERSARC风险组中蒽环类+异环磷酰胺方案HR 0.66(95%CI 0.53-0.83)。
核心结论
- 本研究显示,在PERSARC预测工具分层的高风险患者中,基于蒽环类+异环磷酰胺的化疗对总生存有益,绝对生存获益为11%。
- 然而,在70岁以下原发高级别肢体软组织肉瘤总体人群中,未发现化疗对总生存有益。
研究设计与样本
- 回顾性队列研究,纳入18-70岁原发高级别肢体软组织肉瘤且以治愈为目的手术的患者,共5683例。
- 按PERSARC预测5年OS的33%和66%分位数将患者分为高、中、低风险三组,对应5年OS分别为65.8%和79.8%。
- 采用加权Kaplan-Meier曲线和多变量Cox模型(含风险组与化疗的交互项)分析化疗对总生存的影响。
主要发现
- 加权Kaplan-Meier曲线显示,在总体人群中,任何围手术期化疗及基于蒽环类+异环磷酰胺的化疗均未对总生存显示有益。
- 在高PERSARC风险组中,基于蒽环类+异环磷酰胺化疗的5年OS显著优于未化疗(69.8% vs 59.0%,p=0.004),HR 0.66(95%CI 0.53-0.83)。
关键数值与推荐
- PERSARC风险分组界值为预测5年OS的33%和66%分位数,对应5年OS分别为65.8%和79.8%。
- 高PERSARC风险组中,基于蒽环类+异环磷酰胺化疗的5年OS为69.8%,未化疗为59.0%(p=0.004)。
- 高PERSARC风险组中,基于蒽环类+异环磷酰胺化疗对比未化疗的HR为0.66(95%CI 0.53-0.83)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the study is to assess the effect of perioperative chemotherapy (CTX) in patients with grade II-III extremity soft tissue sarcoma (eSTS) on overall survival (OS) and evaluate whether the PERSARC prediction tool could identify patients with eSTS more likely to benefit from CTX. METHODS: Patients (18-70 years) with primary high-grade eSTS surgically treated with curative intent were included in the retrospective cohort study. The effect of any perioperative CTX and anthracycline + ifosfamide (AI)-based CTX on OS was investigated in three PERSARC-risk groups (high/intermediate/low). The PERSARC-risk groups were defined by the 33% and 66% quantile of the predicted 5-year OS of the study population equal to a 5-year OS of 65.8% and 79.8%, respectively. The effect of CTX on OS was investigated with weighted Kaplan-Meier curves and multivariable Cox models with an interaction between risk group and CTX. RESULTS: This study included 5683 patients. The weighted Kaplan-Meier curves did not demonstrate a beneficial effect of any CTX and AI-based CTX on OS in the overall population. However, in the high PERSARC-risk group the 5-year OS of AI-based CTX was significantly better than no CTX (69.8% vs 59.0%, respectively, p = 0.004) (HR 0.66, 95%CI 0.53-0.83). CONCLUSIONS: This study demonstrated a beneficial effect of AI-based CTX on OS in a selected group of high-risk patients with an absolute survival benefit of 11% as stratified by the PERSARC prediction tool. However, no beneficial effect of CTX on OS was found in the overall population of patients with primary high-grade eSTS younger than 70 years.
引用
- Acem I, van Houdt WJ, Grünhagen DJ, et al. The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. Eur J Cancer. 2022. PMID: 35219025. doi:10.1016/j.ejca.2022.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。